Skip to main content
. Author manuscript; available in PMC: 2024 Apr 2.
Published in final edited form as: Mol Cancer Ther. 2023 Oct 2;22(10):1215–1227. doi: 10.1158/1535-7163.MCT-23-0210

Figure 1.

Figure 1.

In vivo therapeutic efficacy of intratumoral injection of human IL-15 in a MC38 tumor mouse model. A, Tumor growth curves after IL-15 treatment. Mice with MC38 tumors reaching approximatey 50–150 mm3 in volume were used. Human IL-15 (5 μg) was intraperitoneally (IP) or intratumorally (IT) administered to mice (day 0, 2, 4, and 6) and tumor growth was compared among the three groups showing slower growth in IL-15-exposed tumors (n = 7; mean ± SEM; repeated measures two-way ANOVA followed by Tukey’s test); *, p < 0.05; **, p < 0.01. B, Survival curves after IL-15 treatment (n = 7, log–rank test with Bonferroni correction); **, p < 0.01; ****, p < 0.0001. C, Host immune responses after IL-15 treatment. A single dose (5 μg) of IL-15 were intraperitoneally or intratumorally administered to MC38 tumor-bearing mice. One day after IL-15 treatment, the tumors were harvested and analyzed by flow cytometry demonstrating increased number of immune cells in tumors treated with IL-15 IT (n = 4; mean ± SEM; one-way ANOVA followed by Tukey’s test); *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.